SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a...
Hence then, the article about biohaven and sk biopharmaceuticals enter into strategic global licensing agreement for novel kv7 ion channel platform and opakalim lead candidate for epilepsy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy )
Also on site :
- Dolly Parton’s Final Message to Millions of Children Is Breaking Hearts After Her Death: ‘Promise Me’
- Kendra Scott’s Dainty Pumpkin Necklace Is a Festive Finishing Touch for Fall Outfits, and It’s Under $35
- Dolly Parton’s Musical Reach Stretched Beyond Country to Pop and Rock With Unexpected Covers and Collabs